Last updated: September 8, 2026
Empagliflozin is a high-value branded SGLT2 inhibitor marketed primarily as Jardiance and in combination products with metformin hydrochloride, including Synjardy and Synjardy XR. Metformin hydrochloride is a mature, low-cost generic medicine with negligible remaining composition-of-matter exclusivity. The commercial value of the combination is therefore concentrated in empagliflozin, brand access, cardiovascular and renal outcomes data, and protection for fixed-dose formulations.
Jardiance has developed into a multibillion-dollar product for Eli Lilly and Boehringer Ingelheim. Growth has been driven by type 2 diabetes, heart failure and chronic kidney disease indications. The principal medium-term risk is generic empagliflozin entry after the remaining U.S. patent and regulatory protections expire or are narrowed through Paragraph IV litigation.
What are empagliflozin and metformin hydrochloride used for?
Empagliflozin is an oral sodium-glucose cotransporter-2 inhibitor. It lowers blood glucose by increasing urinary glucose excretion and has demonstrated cardiovascular and renal benefits beyond glycemic control.
Metformin hydrochloride is a biguanide that reduces hepatic glucose production. It remains a first-line treatment for type 2 diabetes and is widely available in immediate-release and extended-release generic forms.
The principal products are:
| Product |
Active ingredients |
Sponsor or commercial party |
FDA milestone |
Primary commercial role |
| Jardiance |
Empagliflozin |
Boehringer Ingelheim and Eli Lilly |
Approved 2014 |
Branded empagliflozin |
| Synjardy |
Empagliflozin/metformin HCl |
Boehringer Ingelheim and Eli Lilly |
Approved 2015 |
Fixed-dose combination |
| Synjardy XR |
Empagliflozin/metformin HCl extended release |
Boehringer Ingelheim and Eli Lilly |
Approved 2016 |
Once-daily extended-release combination |
| Generic metformin |
Metformin HCl |
Multiple manufacturers |
Long-established |
Low-cost backbone therapy |
The FDA initially approved Jardiance for glycemic control in adults with type 2 diabetes. Subsequent label expansions covered reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, heart failure benefits and chronic kidney disease risk reduction.[1]
How large is the empagliflozin market?
Empagliflozin is one of the leading SGLT2 inhibitors globally. The competitive class includes dapagliflozin, marketed as Farxiga by AstraZeneca, and canagliflozin, marketed as Invokana by Johnson & Johnson.
Jardiance has benefited from three commercial factors:
- Cardiovascular-outcomes evidence that differentiates it from older glucose-lowering therapies.
- Expansion into heart failure and chronic kidney disease populations, including some patients without diabetes.
- Broad payer adoption supported by guideline inclusion and outcomes-based prescribing.
Eli Lilly has reported Jardiance revenue at approximately the multibillion-dollar level annually, with reported product sales around $7 billion in 2023 across the global collaboration economics reported by the company.[2] Boehringer Ingelheim also reports Jardiance as one of its largest pharmaceutical products, although the two companies do not present revenue in identical formats.
Synjardy and Synjardy XR generate materially less revenue than Jardiance. The combination products improve adherence and prescribing convenience but face direct substitution from generic metformin combined with branded or generic empagliflozin. Their commercial value depends on formulary positioning, copay support and the ability to avoid separate-pill burdens.
What is the financial trajectory for empagliflozin and metformin?
Empagliflozin financial outlook
Empagliflozin remains in the growth phase of its commercial life cycle rather than the mature decline phase. Revenue has expanded through label growth and increased use in cardiology and nephrology.
The financial trajectory can be divided into four periods:
| Period |
Commercial condition |
Financial effect |
| 2014-2016 |
Diabetes launch and early outcomes adoption |
Initial branded growth |
| 2016-2020 |
Cardiovascular benefit and broader diabetes uptake |
Rapid expansion |
| 2021-2023 |
Heart failure and kidney disease use |
Large market expansion |
| 2024 onward |
Broader class competition and future generic preparation |
Continued growth followed by patent-risk discounting |
The highest-value opportunity is no longer limited to glucose control. Heart failure and chronic kidney disease expand the addressable population and reduce dependence on endocrinology prescribing. Those indications also strengthen the clinical rationale for continued use when glycemic control is already adequate.
Revenue pressure will increase before full generic erosion if payers begin requiring lower-cost alternatives, if competing SGLT2 inhibitors receive preferred formulary status, or if generic manufacturers secure launch dates through litigation settlements.
Metformin hydrochloride financial outlook
Metformin is financially mature. Immediate-release and extended-release versions are supplied by numerous generic manufacturers, including large U.S., Indian and European producers. Unit prices are low, supply is competitive and switching costs are limited.
Metformin's economic importance is strategic rather than revenue-based:
- It is a high-volume diabetes therapy.
- It anchors fixed-dose combinations.
- It supports adherence and prescription persistence.
- It contributes little standalone pricing power.
- It does not materially extend the exclusivity of empagliflozin.
The combination of empagliflozin and metformin can preserve some branded value, but metformin does not create a meaningful barrier to generic substitution.
What patents protect empagliflozin and Synjardy?
The principal patent value lies in empagliflozin-related compound, formulation, combination and method-of-use claims. Metformin hydrochloride composition patents are generally expired or commercially irrelevant.
Empagliflozin compound patents
The original empagliflozin patent family was developed by Boehringer Ingelheim and covers C-glucoside SGLT2 inhibitor compounds and related chemical subject matter. The relevant U.S. patents have been subject to patent-term calculations, Orange Book listings and Paragraph IV challenges.
U.S. exclusivity depends on:
- The expiration date of the listed patent claims.
- Any patent-term adjustment or patent-term extension.
- Pediatric exclusivity.
- The scope of claims surviving litigation.
- The launch date agreed in any settlement.
- Whether a generic applicant seeks approval for all indications or uses a section viii carve-out.
The commercial importance of the original compound patent is greater than the importance of metformin-related rights. A successful challenge to the core empagliflozin patent can accelerate broad generic entry across Jardiance and some combination products.
Formulation and fixed-dose combination patents
Synjardy and Synjardy XR may be protected by patents directed to:
- Empagliflozin-metformin combinations.
- Extended-release delivery systems.
- Release profiles and tablet architecture.
- Manufacturing processes.
- Dosage strengths.
- Methods of treating diabetes with the combination.
Formulation patents are usually narrower than composition-of-matter patents. They may delay a particular product, strength or dosage form without blocking every generic empagliflozin product.
A generic manufacturer can potentially avoid a formulation patent by marketing an immediate-release product, changing excipients, using a different release technology or relying on a section viii statement that omits a protected use.
What is the Orange Book status of Jardiance and Synjardy?
Jardiance, Synjardy and Synjardy XR are FDA-approved prescription products. Their Orange Book status depends on the listed patents for the relevant product and dosage form.[3]
The Orange Book is commercially important because it:
- Identifies patents submitted by the approved-product sponsor.
- Establishes the patent certification framework for ANDA applicants.
- Supports Paragraph IV litigation.
- Provides a public reference for listed expiry dates.
- Does not guarantee that every listed patent will survive litigation.
- Does not include every potentially relevant manufacturing or process patent.
The practical distinction is between product-level approval and patent-level blocking power. A generic may obtain FDA approval while remaining subject to a later launch restriction caused by litigation, settlement or a court injunction.
When does empagliflozin lose exclusivity?
Empagliflozin does not have one single global loss-of-exclusivity date. The timing differs by country, dosage form, patent family and litigation outcome.
The U.S. sequence is likely to follow this pattern:
| Exclusivity component |
Commercial effect |
| Core empagliflozin patent rights |
Determines earliest broad generic challenge |
| Formulation patents |
May delay Synjardy XR or selected strengths |
| Pediatric exclusivity |
Can add six months to qualifying protections |
| Regulatory exclusivity |
Usually less important than the patent estate for this small molecule |
| Paragraph IV settlements |
May establish an agreed generic launch date |
| Post-approval patents |
Can create narrower, indication-specific litigation |
The first generic entry may target empagliflozin tablets rather than the full Synjardy franchise. Separate generic metformin is already available, so pharmacies and payers can reproduce much of the combination's therapeutic effect through two prescriptions.
Which companies are challenging empagliflozin patents?
Generic manufacturers commonly evaluating or filing ANDAs for high-value oral diabetes products include Lupin, Zydus, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Dr. Reddy's Laboratories, Cipla, Alembic Pharmaceuticals and other Indian and U.S. suppliers.
The precise active challenger list changes as:
- ANDAs are filed.
- Paragraph IV notices are served.
- Patent owners file infringement complaints.
- Cases settle.
- FDA approvals issue.
- Applicants amend certifications.
- Some products are approved with label carve-outs.
Paragraph IV risk is highest for the core empagliflozin tablet. Synjardy and Synjardy XR face more complex challenges because the applicant must address both the active ingredient and fixed-dose or extended-release patent claims.
A Paragraph IV filing does not mean immediate generic launch. Under the Hatch-Waxman framework, a timely patent-infringement action can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court rulings.[4]
What patent litigation affects Jardiance and Synjardy?
The principal litigation risk is Hatch-Waxman litigation involving Boehringer Ingelheim and its affiliates against ANDA applicants. The cases generally concern:
- Invalidity of empagliflozin compound claims.
- Non-infringement based on the applicant's formulation.
- Obviousness.
- Written description and enablement.
- Patent-term calculations.
- Combination-product claims.
- Extended-release formulation claims.
The strongest litigation position typically comes from a valid compound patent with broad claims covering the active ingredient. Formulation patents are more vulnerable to design-around strategies and may protect only a subset of the market.
Settlement agreements can materially alter the financial trajectory. A settlement may permit an authorized generic, a licensed generic, or a fixed launch date before formal patent expiry. Public settlement terms are often incomplete, so an apparent absence of market entry does not establish that no agreement exists.
Is there biosimilar risk for empagliflozin?
No. Empagliflozin and metformin hydrochloride are chemically synthesized small molecules, not biologics. They face generic-drug risk under the ANDA pathway rather than biosimilar risk under the Biologics Price Competition and Innovation Act.
The relevant competitive threats are:
- Abbreviated new drug applications.
- Paragraph IV certifications.
- Authorized generics.
- Combination-product substitution.
- Formulary movement to dapagliflozin.
- Lower-cost use of generic metformin with a separate SGLT2 inhibitor.
How does Jardiance compare with Farxiga and Invokana?
| Factor |
Jardiance |
Farxiga |
Invokana |
| Active ingredient |
Empagliflozin |
Dapagliflozin |
Canagliflozin |
| Sponsor |
Boehringer Ingelheim and Eli Lilly |
AstraZeneca |
Johnson & Johnson |
| Major growth areas |
Diabetes, heart failure, chronic kidney disease |
Diabetes, heart failure, chronic kidney disease |
Diabetes and cardiovascular-risk reduction |
| Combination with metformin |
Synjardy and Synjardy XR |
Xigduo and Xigduo XR |
Invokamet and Invokamet XR |
| Commercial position |
Leading SGLT2 franchise |
Principal branded competitor |
Smaller position after safety and market pressures |
| Biosimilar risk |
None |
None |
None |
| Generic risk |
Future small-molecule entry |
Future small-molecule entry |
Future small-molecule entry |
Jardiance and Farxiga have the strongest strategic positions because both have expanded beyond diabetes into heart failure and renal disease. Clinical differentiation is less important than formulary access, label breadth, price and remaining patent life.
What generic launch scenarios exist for empagliflozin?
Scenario 1: Delayed broad launch
The core patent survives litigation and generic launch occurs near the effective expiry date. Jardiance retains substantial value until then, although discounts may increase before launch.
Scenario 2: Early at-risk launch
A generic applicant launches after obtaining approval but before final resolution of all patent disputes. This can create rapid price erosion and damages exposure if the patent owner prevails.
Scenario 3: Staggered entry
Generic empagliflozin launches first, while Synjardy XR or selected strengths remain protected by formulation patents. The market then experiences gradual substitution.
Scenario 4: Settlement-controlled entry
Boehringer and Lilly permit one or more generic companies to enter on a negotiated date. The settlement may include supply rights, an authorized generic arrangement or restrictions on certain strengths.
The most damaging scenario for branded revenue is broad, multi-manufacturer entry into empagliflozin tablets combined with continued payer pressure on branded Jardiance.
What geographic coverage does the empagliflozin patent estate have?
The patent estate has commercial relevance in the United States, Europe, Japan, China, Canada, Australia and other major pharmaceutical markets. Protection differs by country because:
- Patent families have different national phase dates.
- Patent-term adjustments vary.
- Supplementary protection certificates may extend European protection.
- Patent validity standards differ.
- Regulatory exclusivity periods are not uniform.
- Generic filing and launch rules vary by jurisdiction.
U.S. patent litigation is the most commercially significant because the United States has the highest branded price and the largest revenue exposure. European entry can occur through country-specific proceedings and centralized or national regulatory routes, while other markets may see faster erosion after local patent expiry.
How strong is the empagliflozin patent estate?
The estate is commercially strong while enforceable core compound claims remain in force. Its strength is lower for the combination franchise because:
- Metformin is generic.
- Fixed-dose products can be designed around.
- Extended-release claims are narrower.
- Separate-pill substitution is feasible.
- Generic manufacturers can target the active ingredient rather than the branded combination.
The principal moat is clinical and commercial as well as legal. Cardiovascular and renal indications support demand, but those benefits do not prevent generic competition after approval and patent barriers fall.
Key Takeaways
- Empagliflozin is the value driver; metformin hydrochloride is a mature generic component.
- Jardiance is a multibillion-dollar franchise owned commercially by Boehringer Ingelheim and Eli Lilly.
- Heart failure and chronic kidney disease indications have expanded the market beyond type 2 diabetes.
- Synjardy and Synjardy XR receive less protection from metformin than from empagliflozin and formulation patents.
- Generic, not biosimilar, competition is the central long-term risk.
- The first meaningful erosion event is likely to involve generic empagliflozin tablets, followed by narrower challenges to fixed-dose and extended-release products.
- Paragraph IV litigation, settlement dates and Orange Book patent scope will determine the timing of U.S. entry.
- The financial decline after generic entry could be rapid because pharmacies can substitute generic empagliflozin and generic metformin separately.
FAQs
Does metformin extend Jardiance patent protection?
No. Metformin hydrochloride does not extend the underlying patent term for empagliflozin. It may be included in separate fixed-dose combination claims, but those claims do not recreate composition-of-matter protection for empagliflozin.
Is Synjardy more protected than Jardiance?
Synjardy may have additional combination and formulation patents, but those rights are narrower than a valid core compound patent. A generic company may challenge the combination directly or market separate empagliflozin and metformin products.
Will generic empagliflozin reduce Jardiance revenue immediately?
Usually, revenue erosion begins with payer substitution and discounts before full pharmacy substitution. The rate accelerates when multiple generic suppliers enter and payers place generic products on preferred tiers.
Can a generic launch empagliflozin for diabetes but exclude heart failure?
Yes. An ANDA applicant may use a section viii statement to omit patented methods of use from its labeling if the remaining indications can be approved and marketed lawfully.
What is the main investment risk for the Jardiance franchise?
The main risk is a faster-than-expected generic entry date caused by invalidation of core patent claims, an at-risk launch, or a settlement that permits generic competition before the expected expiry date.
References
- U.S. Food and Drug Administration. (2023). Jardiance prescribing information.
- Eli Lilly and Company. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements.
